F1Article 5
1.
The competent authority of a Member State may decide to allow the use of vaccines against bluetongue provided that:
(a)
such decision is based on the result of a specific risk assessment carried out by the competent authority;
(b)
the Commission is informed before such vaccination is carried out.
2.
Whenever live attenuated vaccines are used, Member States shall ensure that the competent authority demarcates:
(a)
a protection zone, consisting of at least the vaccination area;
(b)
a surveillance zone, consisting of a part of the Union territory with a depth of at least 50 kilometres extending beyond the limits of the protection zone.